Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

[Guest guest]

http://www.ingentaconnect.com/content/bsc/jvh/2011/00000018/00000008/art00007

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for

HBeAg-negative patients

Authors: Moucari, R.; Boyer, N.; Ripault, M.-P.; Castelnau, C.; Mackiewicz, V.1;

Dauvergne, A.2; Valla, D.; Vidaud, M.2; Chanoine, M.-H. N.1; Marcellin, P.

Source: Journal of Viral Hepatitis, Volume 18, Number 8, 1 August 2011 , pp.

580-586(7)

Publisher: Wiley-Blackwell

Abstract:

Summary.  To assess the impact of sequential therapy with adefovir dipivoxil

(ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA)

and serological (serum HBsAg) response in 20 consecutive HBeAg-negative

patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for

4 weeks and lastly PEG-IFN for 44 weeks. Serum HBV-DNA and HBsAg were

assessed at baseline, during therapy (weeks 20, 44 and 68) and follow-up (weeks

92 and 116). Sustained virological response (SVR) was defined as serum HBV-DNA

<10 000 copies/mL (partial) or <70 copies/mL (complete) 24 weeks after

stopping treatment. A serological response was defined as a serum HBsAg decrease

≥1 log10IU/mL at the end of treatment. Baseline median serum HBV-DNA and

HBsAg levels were 7.6 log10copies/mL and 3.8 log10IU/mL, respectively. Ten

patients (50%) achieved SVR, six of them had partial response and four complete

response. Four patients (20%) achieved serological response. Complete SVRs

showed a major and steep decline in HBsAg level with a median decrease of 0.5,

1.6 and 2.0 log10IU/mL at treatment week 20, 44 and 68, respectively. Partial

SVRs showed a slight and slow decline in serum HBsAg level (0.1, 0.4, and 0.6

log IU/mL at weeks 20, 44 and 68, respectively). On-treatment serum HBsAg

decrease had a high accuracy to predict SVR (AUROC = 0.88). Our results

suggest that sequential therapy might be an interesting strategy for

HBeAg-negative patients. Serum HBsAg kinetics seem to be an accurate tool to

predict SVR. Large clinical trials are needed to explore this strategy with more

potent analogues.

Document Type: Research article

DOI: 10.1111/j.1365-2893.2010.01332.x

Affiliations:1: Hôpital Beaujon, Service de Microbiologie, Clichy, France 2:

Hôpital Beaujon, Service de Biochimie, Clichy, France

Publication date: 2011-08-01

[Guest guest]

http://www.ingentaconnect.com/content/bsc/jvh/2011/00000018/00000008/art00007

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for

HBeAg-negative patients

Authors: Moucari, R.; Boyer, N.; Ripault, M.-P.; Castelnau, C.; Mackiewicz, V.1;

Dauvergne, A.2; Valla, D.; Vidaud, M.2; Chanoine, M.-H. N.1; Marcellin, P.

Source: Journal of Viral Hepatitis, Volume 18, Number 8, 1 August 2011 , pp.

580-586(7)

Publisher: Wiley-Blackwell

Abstract:

Summary.  To assess the impact of sequential therapy with adefovir dipivoxil

(ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA)

and serological (serum HBsAg) response in 20 consecutive HBeAg-negative

patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for

4 weeks and lastly PEG-IFN for 44 weeks. Serum HBV-DNA and HBsAg were

assessed at baseline, during therapy (weeks 20, 44 and 68) and follow-up (weeks

92 and 116). Sustained virological response (SVR) was defined as serum HBV-DNA

<10 000 copies/mL (partial) or <70 copies/mL (complete) 24 weeks after

stopping treatment. A serological response was defined as a serum HBsAg decrease

≥1 log10IU/mL at the end of treatment. Baseline median serum HBV-DNA and

HBsAg levels were 7.6 log10copies/mL and 3.8 log10IU/mL, respectively. Ten

patients (50%) achieved SVR, six of them had partial response and four complete

response. Four patients (20%) achieved serological response. Complete SVRs

showed a major and steep decline in HBsAg level with a median decrease of 0.5,

1.6 and 2.0 log10IU/mL at treatment week 20, 44 and 68, respectively. Partial

SVRs showed a slight and slow decline in serum HBsAg level (0.1, 0.4, and 0.6

log IU/mL at weeks 20, 44 and 68, respectively). On-treatment serum HBsAg

decrease had a high accuracy to predict SVR (AUROC = 0.88). Our results

suggest that sequential therapy might be an interesting strategy for

HBeAg-negative patients. Serum HBsAg kinetics seem to be an accurate tool to

predict SVR. Large clinical trials are needed to explore this strategy with more

potent analogues.

Document Type: Research article

DOI: 10.1111/j.1365-2893.2010.01332.x

Affiliations:1: Hôpital Beaujon, Service de Microbiologie, Clichy, France 2:

Hôpital Beaujon, Service de Biochimie, Clichy, France

Publication date: 2011-08-01

[Guest guest]

http://www.ingentaconnect.com/content/bsc/jvh/2011/00000018/00000008/art00007

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for

HBeAg-negative patients

Authors: Moucari, R.; Boyer, N.; Ripault, M.-P.; Castelnau, C.; Mackiewicz, V.1;

Dauvergne, A.2; Valla, D.; Vidaud, M.2; Chanoine, M.-H. N.1; Marcellin, P.

Source: Journal of Viral Hepatitis, Volume 18, Number 8, 1 August 2011 , pp.

580-586(7)

Publisher: Wiley-Blackwell

Abstract:

Summary.  To assess the impact of sequential therapy with adefovir dipivoxil

(ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA)

and serological (serum HBsAg) response in 20 consecutive HBeAg-negative

patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for

4 weeks and lastly PEG-IFN for 44 weeks. Serum HBV-DNA and HBsAg were

assessed at baseline, during therapy (weeks 20, 44 and 68) and follow-up (weeks

92 and 116). Sustained virological response (SVR) was defined as serum HBV-DNA

<10 000 copies/mL (partial) or <70 copies/mL (complete) 24 weeks after

stopping treatment. A serological response was defined as a serum HBsAg decrease

≥1 log10IU/mL at the end of treatment. Baseline median serum HBV-DNA and

HBsAg levels were 7.6 log10copies/mL and 3.8 log10IU/mL, respectively. Ten

patients (50%) achieved SVR, six of them had partial response and four complete

response. Four patients (20%) achieved serological response. Complete SVRs

showed a major and steep decline in HBsAg level with a median decrease of 0.5,

1.6 and 2.0 log10IU/mL at treatment week 20, 44 and 68, respectively. Partial

SVRs showed a slight and slow decline in serum HBsAg level (0.1, 0.4, and 0.6

log IU/mL at weeks 20, 44 and 68, respectively). On-treatment serum HBsAg

decrease had a high accuracy to predict SVR (AUROC = 0.88). Our results

suggest that sequential therapy might be an interesting strategy for

HBeAg-negative patients. Serum HBsAg kinetics seem to be an accurate tool to

predict SVR. Large clinical trials are needed to explore this strategy with more

potent analogues.

Document Type: Research article

DOI: 10.1111/j.1365-2893.2010.01332.x

Affiliations:1: Hôpital Beaujon, Service de Microbiologie, Clichy, France 2:

Hôpital Beaujon, Service de Biochimie, Clichy, France

Publication date: 2011-08-01

[Guest guest]

http://www.ingentaconnect.com/content/bsc/jvh/2011/00000018/00000008/art00007

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for

HBeAg-negative patients

Authors: Moucari, R.; Boyer, N.; Ripault, M.-P.; Castelnau, C.; Mackiewicz, V.1;

Dauvergne, A.2; Valla, D.; Vidaud, M.2; Chanoine, M.-H. N.1; Marcellin, P.

Source: Journal of Viral Hepatitis, Volume 18, Number 8, 1 August 2011 , pp.

580-586(7)

Publisher: Wiley-Blackwell

Abstract:

Summary.  To assess the impact of sequential therapy with adefovir dipivoxil

(ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA)

and serological (serum HBsAg) response in 20 consecutive HBeAg-negative

patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for

4 weeks and lastly PEG-IFN for 44 weeks. Serum HBV-DNA and HBsAg were

assessed at baseline, during therapy (weeks 20, 44 and 68) and follow-up (weeks

92 and 116). Sustained virological response (SVR) was defined as serum HBV-DNA

<10 000 copies/mL (partial) or <70 copies/mL (complete) 24 weeks after

stopping treatment. A serological response was defined as a serum HBsAg decrease

≥1 log10IU/mL at the end of treatment. Baseline median serum HBV-DNA and

HBsAg levels were 7.6 log10copies/mL and 3.8 log10IU/mL, respectively. Ten

patients (50%) achieved SVR, six of them had partial response and four complete

response. Four patients (20%) achieved serological response. Complete SVRs

showed a major and steep decline in HBsAg level with a median decrease of 0.5,

1.6 and 2.0 log10IU/mL at treatment week 20, 44 and 68, respectively. Partial

SVRs showed a slight and slow decline in serum HBsAg level (0.1, 0.4, and 0.6

log IU/mL at weeks 20, 44 and 68, respectively). On-treatment serum HBsAg

decrease had a high accuracy to predict SVR (AUROC = 0.88). Our results

suggest that sequential therapy might be an interesting strategy for

HBeAg-negative patients. Serum HBsAg kinetics seem to be an accurate tool to

predict SVR. Large clinical trials are needed to explore this strategy with more

potent analogues.

Document Type: Research article

DOI: 10.1111/j.1365-2893.2010.01332.x

Affiliations:1: Hôpital Beaujon, Service de Microbiologie, Clichy, France 2:

Hôpital Beaujon, Service de Biochimie, Clichy, France

Publication date: 2011-08-01